<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575625</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO2011-FP/TRANSTEATOSE</org_study_id>
    <nct_id>NCT02575625</nct_id>
  </id_info>
  <brief_title>Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis</brief_title>
  <acronym>TRANSTEATOSE</acronym>
  <official_title>Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Echosens</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis of this study is the existence of a relation between parameters measured by&#xD;
      FibroScan® FS 502 according to our non invasive method and liver steatosis condition.&#xD;
&#xD;
      This proof of concept validation is made up of two steps:&#xD;
&#xD;
        -  Step 1: feasibility study of the method on 10 healthy volunteers&#xD;
&#xD;
        -  Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25&#xD;
           between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom&#xD;
           the histological answer is clean steatosis (NAFLD).&#xD;
&#xD;
      Experimental procedures consist in:&#xD;
&#xD;
        -  Fibroscan measure, preceded by tracking ultrasonography.&#xD;
&#xD;
        -  liver MRI (for substudy about MRI comparison, in step 2)&#xD;
&#xD;
        -  a blood test for biological assessment of liver functions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis of liver lipid overload (named liver steatosis), unrelated to alcohol consumption,&#xD;
      still mainly based on histological exam of the liver. An histological continuity exists going&#xD;
      from clean liver steatosis (Non Alcoholic Fatty Liver Disease, NAFLD) to steatohepatitis with&#xD;
      signs of inflammation and tissue fibrosis (Non Alcoholic Steato-Hepatitis, NASH). It's now&#xD;
      well-known that disease can evolve to cirrhosis and its complications.&#xD;
&#xD;
      Hypothesis of this study is the existence of a relation between parameters measured by&#xD;
      FibroScan® FS 502 according to our non invasive method and liver steatosis condition.&#xD;
&#xD;
      This proof of concept validation is made up of two steps:&#xD;
&#xD;
        -  Step 1: feasibility study of the method on 10 healthy volunteers&#xD;
&#xD;
        -  Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25&#xD;
           between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom&#xD;
           the histological answer is clean steatosis (NAFLD).&#xD;
&#xD;
      Measures on healthy volunteers enable to do an intra-operator reproductibility analysis, a&#xD;
      study of an age effect and a search of potential mechanic aging of the liver.&#xD;
&#xD;
      Experimental procedures consist in:&#xD;
&#xD;
        -  Fibroscan measure, preceded by tracking ultrasonography.&#xD;
&#xD;
        -  liver MRI (for substudy about MRI comparison, in step 2)&#xD;
&#xD;
        -  a blood test for biological assessment of liver functions&#xD;
&#xD;
      The final aim of this study is to propose a device enable medical community to do in vivo&#xD;
      hepatic rheology observation, highly correlated to liver lipid overload. After&#xD;
      industrialization of this innovation, this diffusion could making easier patients follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viscosity in Pa.s</measure>
    <time_frame>One day</time_frame>
    <description>Digital files recorded by medical device will be mathematically processed for extracting elasticity G' and viscosity G'' curves in accordance with the frequency. These curves use to identify the 5 parameters: mu(M), eta(M), alpha, mu(V), eta(V); which describe visco-elasticity variations with frequency thanks to an Matlab algorithm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elasticity in kPa</measure>
    <time_frame>One day</time_frame>
    <description>Digital files recorded by medical device will be mathematically processed for extracting elasticity G' and viscosity G'' curves in accordance with the frequency. These curves use to identify the 5 parameters: mu(M), eta(M), alpha, mu(V), eta(V); which describe visco-elasticity variations with frequency thanks to an Matlab algorithm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproductibility quantification in arbitrary unit</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>The 5 estimated parameters (which describe visco-elasticity) will be used to quantify the medical device reproductibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age in years</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>The 5 estimated parameters (which describe visco-elasticity) and the age oh the healthy volunteers wil be used to study an age effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver signal intensity changes in decibel</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Adiposis charge will be assessed by measure of liver signal intensity decrease on T1 sequence in phase opposition compared to in phase signal, after correction by iron quantity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Liver Steatosis</condition>
  <arm_group>
    <arm_group_label>Fibroscan exam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).&#xD;
Experimental procedures consist in:&#xD;
Fibroscan measure, preceded by tracking sonography.&#xD;
liver MRI (for substudy about MRI comparison, in step 2)&#xD;
a blood test for biological assessment of liver functions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fibroscan</intervention_name>
    <description>Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.</description>
    <arm_group_label>Fibroscan exam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test for biological assessment of liver function</intervention_name>
    <description>Blood test for biological assessment of liver function</description>
    <arm_group_label>Fibroscan exam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Liver MRI</description>
    <arm_group_label>Fibroscan exam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects - Steps 1 and 2&#xD;
&#xD;
               -  Age between 18 and 65 years old (2 age groups for step 2 : 18-30 et 40-65&#xD;
                  years-old)&#xD;
&#xD;
               -  Written inform consent form signed&#xD;
&#xD;
               -  Affiliated to medical insurance&#xD;
&#xD;
               -  Alcohol consumption d'alcool &lt; 20g/j for women, &lt;30g/j for men&#xD;
&#xD;
          -  Patients with liver steatosis - Step 2&#xD;
&#xD;
               -  More than 18 years -old&#xD;
&#xD;
               -  Written inform consent form signed&#xD;
&#xD;
               -  Affiliated to medical insurance&#xD;
&#xD;
               -  Patients with clean steatosis confirmed by histological results of a liver biopsy&#xD;
                  done the previous month&#xD;
&#xD;
               -  Alcohol consumption d'alcool &lt; 20g/j for women, &lt;30g/j for men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects - Step 1&#xD;
&#xD;
               -  Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks&#xD;
&#xD;
               -  Pregnant women, lactating women, and women in age for procreation and without&#xD;
                  reliable contraception&#xD;
&#xD;
               -  Presence of ascites&#xD;
&#xD;
               -  Person under guardianship&#xD;
&#xD;
          -  Healthy subjects - Step 2&#xD;
&#xD;
               -  Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks&#xD;
&#xD;
               -  Pregnant women, lactating women, and women in age for procreation and without&#xD;
                  reliable contraception&#xD;
&#xD;
               -  Contraindication to MRI&#xD;
&#xD;
               -  Presence of ascites&#xD;
&#xD;
               -  Person under guardianship&#xD;
&#xD;
          -  Healthy subjects - Steps 1 and 2&#xD;
&#xD;
               -  Presence of liver tumor or ascites (diagnosed with MRI or ultrasonography)&#xD;
&#xD;
               -  Abnormal liver function tests (increase of transaminases, gammaGT)&#xD;
&#xD;
          -  Patients with liver steatosis - Step 2&#xD;
&#xD;
               -  Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks&#xD;
&#xD;
               -  Pregnant women, lactating women, and women in age for procreation and without&#xD;
                  reliable contraception&#xD;
&#xD;
               -  Contraindication to MRI&#xD;
&#xD;
               -  Presence of ascites&#xD;
&#xD;
               -  liver tumor&#xD;
&#xD;
               -  Serology anti VHC+ or Ag HBs+&#xD;
&#xD;
               -  Infection by HIV&#xD;
&#xD;
               -  Auto-immun hepatitis&#xD;
&#xD;
               -  Genetic hemochromatosis, Wilson disease, lake of alpha-1-antitrypsin&#xD;
&#xD;
               -  Fibrosis or liver cirrhosis at biopsy&#xD;
&#xD;
               -  Person under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic PATAT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic PATAT, MD, PhD</last_name>
    <phone>0247478209</phone>
    <email>patat@med.univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Marc PERANAU, MD</last_name>
    <email>jm.perarnau@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic PATAT, MD, PhD</last_name>
      <phone>0247478209</phone>
      <email>patat@med.univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Marc PERARNAU, MD</last_name>
      <email>jm.perarnau@chu-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frederic PATAT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie GISSOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc PERARNAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick BACQ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis D'ALTEROCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://cic-it-tours.fr/</url>
    <description>Clinical Investigation Center - Technological Innovations</description>
  </link>
  <link>
    <url>http://www.chu-tours.fr/</url>
    <description>University Hospital of Tours</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver steatosis</keyword>
  <keyword>Steatohepatitis</keyword>
  <keyword>Fibroscan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

